Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Needham initiated coverage on Arcellx Inc (NASDAQ:ACLX) with a Buy rating and a price target of $31. Arcellx’s lead program and main…
B. Riley Securities Assumes Livent at Neutral, Announces Price Target of $32
B. Riley Securities analyst Matthew Key assumes Livent (NYSE:LTHM) with a Neutral rating and announces Price Target of $32.
B. Riley Securities Assumes Nouveau Monde Graphite at Buy, Announces Price Target of $7
B. Riley Securities analyst Matthew Key assumes Nouveau Monde Graphite (NYSE:NMG) with a Buy rating and announces Price Target of $7.
B. Riley Securities Assumes Lithium Americas at Buy, Announces Price Target of $41
B. Riley Securities analyst Matthew Key assumes Lithium Americas (NYSE:LAC) with a Buy rating and announces Price Target of $41.
B. Riley Securities Assumes Piedmont Lithium at Buy
B. Riley Securities analyst Matthew Key assumes Piedmont Lithium (NASDAQ:PLL) with a Buy rating.
B. Riley Securities Initiates Coverage On 5E Advanced Materials with Buy Rating, Announces Price Target of $20
B. Riley Securities analyst Matthew Keating initiates coverage on 5E Advanced Materials (NASDAQ:FEAM) with a Buy rating and announces Price Target of $20.
Needham Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $31
Needham analyst Gil Blum initiates coverage on Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of $31.
B of A Securities Reinstates Underperform on Charah Solns
B of A Securities analyst Sherif El-Sabbahy reinstates Charah Solns (NYSE:CHRA) with a Underperform.
Ladenburg Thalmann Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $15
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Buy rating and announces Price Target of $15.